688658 悦康药业
午间休市 07-01 11:29:59
资讯
新帖
简况
6月29日悦康药业涨5.17%,富国医药创新股票A基金重仓该股
证券之星 · 06-29 16:46
6月29日悦康药业涨5.17%,富国医药创新股票A基金重仓该股
新股消息 | 悦康药业(688658.SH)港股IPO招股书失效
智通财经 · 06-29 06:39
新股消息 | 悦康药业(688658.SH)港股IPO招股书失效
悦康药业(688658.SH):YKYY017雾化吸入剂预防和治疗冠状病毒相关的呼吸道感染的适应症获FDA临床试验批准
智通财经 · 06-26
悦康药业(688658.SH):YKYY017雾化吸入剂预防和治疗冠状病毒相关的呼吸道感染的适应症获FDA临床试验批准
每周股票复盘:悦康药业(688658)子公司撤回药品注册并计提减值
证券之星 · 06-20
每周股票复盘:悦康药业(688658)子公司撤回药品注册并计提减值
悦康药业最新公告:子公司撤回通络健脑片药品注册申请
证券之星 · 06-17
悦康药业最新公告:子公司撤回通络健脑片药品注册申请
每周股票复盘:悦康药业(688658)因股价跌幅达15%登龙虎榜
证券之星 · 06-07
每周股票复盘:悦康药业(688658)因股价跌幅达15%登龙虎榜
6月5日悦康药业(688658)龙虎榜数据:机构净卖出6322.78万元,北向资金净买入604.63万元
证券之星 · 06-05
6月5日悦康药业(688658)龙虎榜数据:机构净卖出6322.78万元,北向资金净买入604.63万元
6月5日悦康药业跌15.77%,富国医药创新股票A基金重仓该股
证券之星 · 06-05
6月5日悦康药业跌15.77%,富国医药创新股票A基金重仓该股
每周股票复盘:悦康药业(688658)控股股东部分股份司法拍卖完成过户
证券之星 · 05-31
每周股票复盘:悦康药业(688658)控股股东部分股份司法拍卖完成过户
股市必读:5月28日悦康药业发生1笔大宗交易 成交金额483.21万元
证券之星 · 05-29
股市必读:5月28日悦康药业发生1笔大宗交易 成交金额483.21万元
公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务
格隆汇 · 05-07
公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务
悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目
智通财经 · 05-07
悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目
悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地
美股速递 · 05-07
悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地
5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股
证券之星 · 05-07
5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股
股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%
证券之星 · 05-06
股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%
每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元
证券之星 · 05-02
每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元
悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%
中金财经 · 04-30
悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%
图解悦康药业一季报:第一季度单季净利润同比增长32.81%
证券之星 · 04-29
图解悦康药业一季报:第一季度单季净利润同比增长32.81%
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
证券之星 · 04-26
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
证券之星 · 04-22
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
加载更多
公司概况
公司名称:
悦康药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-24
主营业务:
悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。
发行价格:
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":13.5,"timestamp":1782876599000,"preClose":12.86,"halted":0,"volume":10683807,"delay":0,"changeRate":0.0498,"floatShares":450000000,"shares":450000000,"eps":-0.5472,"marketStatus":"午间休市","change":0.64,"latestTime":"07-01 11:29:59","open":12.75,"high":13.53,"low":12.32,"amount":137000000,"amplitude":0.0941,"askPrice":13.52,"askSize":50,"bidPrice":13.5,"bidSize":878,"shortable":0,"etf":0,"ttmEps":-0.5472,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782882000000},"marketStatusCode":3,"adr":0,"adjPreClose":12.86,"symbolType":"stock_kcb","openAndCloseTimeList":[[1782869400000,1782876600000],[1782882000000,1782889200000]],"highLimit":14.15,"lowLimit":11.57,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":1.76,"roa":"--","roe":"--","epsLYR":-0.59,"committee":0.662409,"marketValue":6075000000,"turnoverRate":0.0237,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-02。","floatMarketCap":6075000000},"requestUrl":"/m/hq/s/688658/","defaultTab":"news","newsList":[{"id":"2647322503","title":"6月29日悦康药业涨5.17%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322503?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:46","pubTimestamp":1782722800,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日悦康药业涨5.17%创60日新低,收盘报13.01元,换手率3.43%,成交量15.42万手,成交额1.98亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","09939","BK1515","688658","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647349331","title":"新股消息 | 悦康药业(688658.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2647349331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647349331?lang=zh_cn&edition=full","pubTime":"2026-06-29 06:39","pubTimestamp":1782686354,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,悦康药业集团股份有限公司于2025年12月29日所递交的港股招股书满6个月,于2026年6月29日失效,递表时中信证券为其独家保荐人。据此前招股书,悦康药业是一家生物制药公司,专注于研究、开发、生产和商业化四种模式的疗法:寡核苷酸、信使核糖核酸疫苗、多肽和中药创新药。悦康通 在中国的医院覆盖面广泛,包括三级及二级医院,用于管理脑血管和外周血管障碍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","IPOS","688658","BK4588","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646330402","title":"悦康药业(688658.SH):YKYY017雾化吸入剂预防和治疗冠状病毒相关的呼吸道感染的适应症获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2646330402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646330402?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:42","pubTimestamp":1782463350,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业 发布公告,公司于近日获得美国食品药品监督管理局关于同意YKYY017雾化吸入剂用于预防和治疗冠状病毒相关的呼吸道感染的临床试验申请的函告。本次新增冠状病毒相关的呼吸道感染适应症,标志着该管线布局从单一病毒向重要呼吸道病毒谱全面拓展,实现广谱冠状病毒呼吸道感染的覆盖,为易感人群提供更全面的防治选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644066872","title":"每周股票复盘:悦康药业(688658)子公司撤回药品注册并计提减值","url":"https://stock-news.laohu8.com/highlight/detail?id=2644066872","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644066872?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:30","pubTimestamp":1781897432,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,悦康药业报收于13.18元,较上周的13.52元下跌2.51%。本周,悦康药业6月15日盘中最高价报13.78元。悦康药业当前最新总市值59.31亿元,在化学制药板块市值排名77/150,在两市A股市值排名2912/5206。本周关注点公司公告汇总:子公司撤回通络健脑片注册申请,拟全额计提5,723.07万元资产减值准备。项目累计支出约5,723.07万元,已出现减值迹象,拟全额计提资产减值准备。本次撤回不影响公司当前生产经营及现有产品销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644271762","title":"悦康药业最新公告:子公司撤回通络健脑片药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2644271762","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644271762?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:49","pubTimestamp":1781689782,"startTime":"0","endTime":"0","summary":"悦康药业(688658.SH)公告称,公司子公司广州悦康生物制药有限公司近日收到国家药监局通知,同意撤回通络健脑片的药品注册申请。该药品主治血管性痴呆,基于国家药监局最新审评建议,公司决定主动撤回申请,并将进一步补充临床研究病例后再次提交。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700031114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641169122","title":"每周股票复盘:悦康药业(688658)因股价跌幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2641169122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641169122?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:22","pubTimestamp":1780766532,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,悦康药业报收于13.73元,较上周的17.82元下跌22.95%。本周,悦康药业6月1日盘中最高价报18.24元。本周关注点交易信息汇总:悦康药业因日收盘价格跌幅达到15%登上龙虎榜交易信息汇总:此次为近5个交易日内第1次上榜交易信息汇总沪深交易所2026年6月5日公布的交易公开信息显示,悦康药业因有价格涨跌幅限制的日收盘价格跌幅达到15%的前五只证券登上龙虎榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641111515","title":"6月5日悦康药业(688658)龙虎榜数据:机构净卖出6322.78万元,北向资金净买入604.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641111515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641111515?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:40","pubTimestamp":1780652427,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年6月5日公布的交易公开信息显示,悦康药业因有价格涨跌幅限制的日收盘价格跌幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年6月5日收盘,悦康药业报收于13.73元,下跌15.77%,换手率8.54%,成交量38.41万手,成交额5.46亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出6322.78万元,北向资金合计净买入604.63万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500030738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641115053","title":"6月5日悦康药业跌15.77%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641115053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641115053?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:38","pubTimestamp":1780648713,"startTime":"0","endTime":"0","summary":"证券之星消息,6月5日悦康药业跌15.77%创60日新低,收盘报13.73元,换手率8.54%,成交量38.41万手,成交额5.46亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK1515","09939","BK1574","BK1161","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639048656","title":"每周股票复盘:悦康药业(688658)控股股东部分股份司法拍卖完成过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2639048656","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639048656?lang=zh_cn&edition=full","pubTime":"2026-05-31 02:41","pubTimestamp":1780166469,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,悦康药业报收于17.82元,较上周的18.66元下跌4.5%。本周,悦康药业5月25日盘中最高价报19.25元。交易信息汇总5月28日悦康药业发生1笔大宗交易,成交金额483.21万元。公司公告汇总悦康药业集团股份有限公司发布公告,控股股东阜阳京悦永顺信息咨询有限公司所持公司1,720,000股无限售流通股因司法拍卖已完成过户登记,过户股份已同步解除司法冻结。截至公告日,京悦永顺仍有3,950,654股股份被司法冻结,占公司总股本0.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639906756","title":"股市必读:5月28日悦康药业发生1笔大宗交易 成交金额483.21万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639906756","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639906756?lang=zh_cn&edition=full","pubTime":"2026-05-29 01:17","pubTimestamp":1779988631,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘,悦康药业报收于17.99元,下跌3.54%,换手率2.35%,成交量10.59万手,成交额1.92亿元。大宗交易5月28日悦康药业发生1笔大宗交易,成交金额483.21万元。公司公告汇总关于控股股东所持公司部分股份被司法拍卖完成过户登记的公告悦康药业集团股份有限公司发布公告,控股股东阜阳京悦永顺信息咨询有限公司所持公司1,720,000股无限售流通股因司法拍卖已完成过户登记,过户股份已同步解除司法冻结。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633572125","title":"公告精选︱悦康药业:拟投资10亿元建设核酸药物基地项目;金螳螂:目前未从事商业航天核心产业,亦未开展数据中心算力运营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633572125","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633572125?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:17","pubTimestamp":1778163460,"startTime":"0","endTime":"0","summary":"卡倍亿:拟发行可转债募资不超过5.1亿元","market":"fut","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4659337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["688658","BK0180","002081","UFO","BK0145","BK0239","BK0183","BK0188","DTCR","BLOK","BK0070","BK4564","BK0178","BK0257","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633148828","title":"悦康药业(688658.SH)拟在杭州投资10亿元建设核酸药物基地项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2633148828","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633148828?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:33","pubTimestamp":1778150031,"startTime":"0","endTime":"0","summary":"公司全资子公司杭州天龙药业有限公司为唯一投资方及项目实施主体。本次投资旨在依托杭州生物医药产业集聚、高端人才汇聚及产业配套完善的区位优势,承接公司现有核酸药物在研管线的研发及产业化,满足产品上市后的量产保障需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121270385","title":"悦康药业拟斥资约10亿元在杭州建设核酸药物生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=1121270385","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121270385?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:24","pubTimestamp":1778149454,"startTime":"0","endTime":"0","summary":"悦康药业集团宣布,公司计划投资约10亿元人民币,在杭州市打造核酸药物生产基地。这一重大投资举措标志着公司正式布局核酸药物这一前沿生物医药领域。\n核酸药物作为新一代生物技术药物,在遗传性疾病、肿瘤治疗等领域展现出巨大潜力。该生产基地的建设将进一步完善悦康药业在创新药物领域的产业布局,提升公司在生物医药领域的核心竞争力。\n此次投资预计将带动当地生物医药产业发展,创造更多就业机会,同时也将助力杭州市打造生物医药产业新高地。项目建成后,将显著提升悦康药业在核酸药物领域的研发和生产能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633370116","title":"5月7日悦康药业涨5.21%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633370116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633370116?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:33","pubTimestamp":1778142828,"startTime":"0","endTime":"0","summary":"证券之星消息,5月7日悦康药业涨5.21%,收盘报21.21元,换手率2.95%,成交量13.28万手,成交额2.75亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为11.12亿元,最新净值1.6834,较上一交易日上涨0.45%,近一年上涨24.36%。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700026719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658","BK1515","BK1161","09939","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633922227","title":"股市必读:悦康药业(688658)股东户数1.48万户,较上期增加13.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633922227","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633922227?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:05","pubTimestamp":1778015116,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,悦康药业报收于19.6元,上涨1.71%,换手率2.48%,成交量11.14万手,成交额2.19亿元。来自公司公告汇总:悦康药业2026年第一季度营业收入为5.56亿元,同比下降3.70%;净利润为-3310.60万元,亏损同比收窄。股本股东变化股东户数变动截至2026年3月31日,悦康药业股东户数为1.48万户,较2月28日增加1745.0户,增幅13.4%;户均持股数量由上期的3.46万股下降至3.05万股,户均持股市值为52.21万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628423","title":"每周股票复盘:悦康药业(688658)Q1净亏收窄至-3310.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632628423?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:32","pubTimestamp":1777671133,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,悦康药业报收于19.6元,较上周的19.28元上涨1.66%。本周,悦康药业4月30日盘中最高价报20.14元。本周关注点来自业绩披露要点:悦康药业2026年一季报显示归母净利润为-3310.6万元,同比上升32.81%。股本股东变化截至2026年3月31日,悦康药业股东户数为1.48万户,较2月28日增加1745.0户,增幅13.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631380576","title":"悦康药业(688658)披露2026年第一季度报告,4月30日股价上涨1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631380576","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631380576?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:36","pubTimestamp":1777545379,"startTime":"0","endTime":"0","summary":"公司于2026年4月30日披露《2026年第一季度报告》。公告显示,悦康药业2026年第一季度营业收入为556,037,071.94元,同比下降3.70%;归属于上市公司股东的净利润为-33,106,026.51元,亏损同比收窄;经营活动产生的现金流量净额为44,470,251.00元,同比下降45.13%;研发投入合计92,647,729.79元,占营业收入比例为16.66%;总资产为5,187,150,678.66元,归属于上市公司股东的所有者权益为3,282,101,354.88元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260430/32194684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516858","title":"图解悦康药业一季报:第一季度单季净利润同比增长32.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631516858?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:51","pubTimestamp":1777463511,"startTime":"0","endTime":"0","summary":"证券之星消息,悦康药业2026年一季报显示,一季度公司主营收入5.56亿元,同比下降3.7%;归母净利润-3310.6万元,同比上升32.81%;扣非净利润-3734.44万元,同比上升30.16%;负债率36.92%,投资收益77.99万元,财务费用385.75万元,毛利率56.93%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630807747","title":"每周股票复盘:悦康药业(688658)募投项目变更用于新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807747?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:31","pubTimestamp":1777156260,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,悦康药业报收于19.28元,较上周的19.93元下跌3.26%。本周,悦康药业4月23日盘中最高价报20.46元。悦康药业当前最新总市值86.76亿元,在化学制药板块市值排名64/150,在两市A股市值排名2273/5200。公司公告汇总悦康药业集团股份有限公司因部分募投项目变更及结项,将节余募集资金用于新增募投项目“小核酸药物及mRNA疫苗研发项目”及永久补充流动资金。专户仅用于特定募投项目募集资金的存放与使用,不得存放非募集资金或作其他用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015184","title":"4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015184?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:30","pubTimestamp":1776846615,"startTime":"0","endTime":"0","summary":"证券之星消息,4月22日悦康药业涨5.49%,收盘报19.8元,换手率3.02%,成交量13.59万手,成交额2.64亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为9.48亿元,最新净值1.717,较上一交易日下跌1.05%,近一年上涨33.73%。该公募基金现任基金经理为赵伟 王超。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK0239","159938","BK1161","BK1574","688658","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782878608229,"stockEarnings":[{"period":"1week","weight":-0.0613},{"period":"1month","weight":-0.2783},{"period":"3month","weight":-0.3267},{"period":"6month","weight":-0.4312},{"period":"1year","weight":-0.3246},{"period":"ytd","weight":-0.4312}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.0316},{"period":"1year","weight":0.1887},{"period":"ytd","weight":0.0316}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14764人(较上一季度增加13.40%)","perCapita":"30479股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}